Dermata Therapeutics Inc. has released a corporate presentation highlighting their advancements in dermatology treatments. The company showcases their unique, multi-use topical platform technology targeting the large medical and aesthetic dermatology market. Key developments include Xyngari, a once-weekly topical treatment for acne, which has shown statistically significant results in the STAR-1 Phase 3 study. A second Phase 3 study, STAR-2, is slated to begin in 2025. Additionally, Dermata's program for psoriasis has completed a positive Phase 1b study, and their DMT410 product for hyperhidrosis is planning a Phase 2a trial with DAXXIFY following a successful Phase 1 proof-of-concept with BOTOX. The presentation also outlines the market opportunities within dermatology, including a prevalence of 50 million acne cases in the US alone, and a growing demand for hyperhidrosis treatments. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.